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Abstract
Background: The etiology of autism spectrum disorders (ASD) is largely determined by different genetic factors of variable
impact. This genetic heterogeneity could be a factor to explain the clinical heterogeneity of autism spectrum disorders.
Here, a first attempt is made to assess whether genetically more homogeneous ASD groups are associated with decreased
phenotypic heterogeneity with respect to their autistic symptom profile.
Methodology: The autistic phenotypes of ASD subjects with 22q11 deletion syndrome (22q11DS) and ASD subjects with
Klinefelter Syndrome (KS) were statistically compared to the symptom profile of a large (genetically) heterogeneous ASD
sample. Autism diagnostic interview-revised (ADI-R) variables were entered in different statistical analyses to assess
differences in symptom homogeneity and the feasibility of discrimination of group-specific ASD-symptom profiles.
Principal Findings: The results showed substantially higher symptom homogeneity in both the genetic disorder ASD
groups in comparison to the heterogeneous ASD sample. In addition, a robust discrimination between 22q11-ASD and KS-
ASD and idiopathic ASD phenotypes was feasible on the basis of a reduced number of autistic scales and symptoms. The
lack of overlap in discriminating subscales and symptoms between KS-ASD and 22q11DS-ASD suggests that their autistic
symptom profiles cluster around different points in the total diagnostic space of profiles present in the general ASD
population.
Conclusion: The findings of the current study indicate that the clinical heterogeneity of ASDs may be reduced when
subgroups based on a specific genotype are extracted from the idiopathic ASD population. The current strategy involving
the widely used ADI-R offers a relatively straightforward possibility for assessing genotype-phenotype ASD relationships.
Reverse phenotype strategies are becoming more feasible, given the accumulating evidence for the existence of genetic
variants of large effect in a substantial proportion of the ASD population.
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Introduction
Autism spectrum disorders (ASDs) delineate a group of
behaviorally-defined disorders including autism, PDD-NOS, and
Asperger syndrome.
Many efforts are being made to address the clinical heteroge-
neity of ASDs. At the same time, the diversity of genetic findings in
the past decade indicate that ASDs should also be considered
genetically heterogeneous [1,2]. This raises the question to what
extent the clinical heterogeneity can be explained by the
underlying genetic heterogeneity of ASDs. In this study we will
address this issue through the assessment of the homogeneity of the
ASD phenotype in genetically more homogenous samples.
In addition to the growing number of genetic ASD susceptibility
loci with small effect sizes, recent studies have described new
‘‘causative’’ genetic variants in ASDs that are assumed to have a
large impact on ASDs [3,4]. They are thought account for about
10–20% of ASD cases [1,4,5]. These risk variants are likely to
show incomplete penetrance and imperfect segregation with
disease as most variants have also been observed in non-autistic
controls [5,6]. Furthermore, several ASD variants have been
shown to cause brain disorders other than ASD, including
schizophrenia, mental retardation and epilepsy [1,6]. This
combination of incomplete penetrance and pleiotropic phenotypes
could indicate that these loci cause a global disruption in brain
development, making it more vulnerable to develop a range of
different brain disorders. Efforts are required to distinguish distinct
aspects of those brain disorders that are caused by these genetic
variants with large effect, versus aspects that result from various
other (environmental and/or genetic) hits.
A logical starting point would be to assess whether at all, ASD
cases ascertained for a particular genetic variant display distinct
autistic characteristics. This model can be considered probable
when cases carrying the same genetic variant are found to share
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most cases in the idiopathic ASD population. The probability of
genetic ASD subphenotypes can be illustrated by Rett syndrome
(RTT). A more homogeneous profile of autistic symptoms together
with non-autistic symptoms has led to the description of the RTT
genetic subphenotype that is formally classified in the DSM-IV-
TR as an ASD subtype. RTT is a progressive neurodevelopmental
disorder that manifests in girls during early childhood [7,8].
Mutations in MECP2 gene are found in more than 95% of classic
RTT cases [9,10]. Patients with RTT appear to develop normally
up to 6–18 months of age. Deceleration of head growth is often the
presenting symptom. This is often accompanied by general growth
retardation, weight loss, and a weak posture and ataxia [7]. Social
withdrawal and loss of language become apparent at early age.
Most patients progressively develop stereotypic hand wringing or
washing movements. Other frequent autistic features include
expressionless face, hypersensitivity to sound, lack of eye-to-eye
contact and unresponsiveness to social cues [8]. This illustrates
that both specific autistic and non-autistic features characterize
RTT. Importantly, the RTT autistic features are also present
among the general population of autistic individuals though
probably in a much lower frequency.
The modest recurrence of most identified large risk variants so
far precludes the inclusion of adequate carrier numbers to evaluate
the specificity of the autistic subphenotype per variant. Each of
these variants on its own represents only a small proportion (at
most 1–2%) of the ASD population [4,11]. Genetic disorders such
as RTT that are frequently associated with ASD have associated
features such as congenital malformations or somatic disorders
that enhance the chance of clinical detection. Therefore, a focus
on ASD subjects ascertained for particular a well defined genetic
disorder enables the inclusion of larger numbers. Importantly,
similar to the newly discovered genetic variants of large effects,
most genetic disorders are associated with ASD only in a fraction
of affected subjects, thus the defining variants in these disorders
also display incomplete penetrance. This warrants a focus on
subsets of individuals with a particular genetic disorder that are
diagnosed with ASD which could possibly precipitate the impact
of a particular variant on autistic symptomatology [1].
As a proof of concept we studied the ASD phenotype of ASD
subjects with 22q11 deletion syndrome (22q11DS) and Klinefelter
syndrome (KS, 47 XXY). 22q11DS and KS subjects without an
ASD classification were excluded. 22q11DS and KS are relatively
frequent disorders affecting 1–2,000–4,000 and 1–700 respectively
[12–14]. Both are clinically defined genetic disorders like RTT
and increased rates of ASD have been described in both 22q11DS
and KS subjects [15–17]. The presence of both disorders has also
previously been described among populations of subjects with
ASD [18–20].
The structure of the ASD phenotype associated with 22q11DS
and KS was compared to a large a large genetically heterogeneous
sample of ASD subjects in different statistical analyses involving
standard autistic measurements. The analyses aimed to assess
differences in symptom homogeneity and the feasibility of
differentiation of group-specific ASD-symptom profiles.
Results
We compared the autism symptom profile of 39 subjects with
22q11DS and ASD and 14 subjects with KS and ASD to a large
genetically heterogeneous sample of 372 ASD subjects (further
referred to as the heterogeneous ASD sample). Autism diagnostic
interview-revised (ADI-R) algorithm variable scores were entered
in the analyses to evaluate differences in symptom homogeneity
and the feasibility of ASD genetic subphenotype discrimination.
Table 1 shows the basic characteristics of the 22q11DS-ASD, KS-
ASD and heterogeneous ASD samples. Correlations in the
heterogeneous ASD sample between IQ scores and the different
ADI-R outcome scores were virtually negligible (20.10,r,0.10).
Therefore IQ was considered irrelevant to the outcome of the
statistical comparisons with the genetic disorder ASD samples.
Symptom homogeneity
Symptom homogeneity was operationalized as the (inverse of
the) mean number of ADI-R algorithm symptom (called ‘‘items’’
in the ADI-R, see Tables S1 and S2) scores within each ASD
group on which the subjects scored clearly in the autistic range, i.e.
ADI-R item score =2. The mean number of ADI-R items on
which the subjects with ASD reached the autism criterion scores
differed significantly between the genetic disorder (22q11DS-ASD
and KS-ASD) ASD samples and the heterogeneous ASD sample
[F(2,423) =24.13, P,.0001, gp
2 =.102] which indicates
increased symptom homogeneity in both the genetic disorder
ASD samples. Post-hoc multiple comparisons with Bonferroni
correction, showed that the average number of ADI-R items that
reached the ADI-R autism criterion score (eg, score =2) in the
22q11DS (10.28 items, SD=4.46) and the KS (11.07 items,
SD=5.44) subjects with ASD was much lower (P,.00001, resp.
P,.002) than in the heterogeneous ASD sample (16.59 items,
SD=6.14) (see Figure 1).
Discrimination of symptom profiles
Discriminant analyses (DA) were performed to determine
whether the genetic disorder ASD subsamples (22q11DS and
KS with ASD) could be differentiated from the heterogeneous
ASD sample on the basis of ADI-R label scores and ADI-R item
scores, respectively. The success of the predictive ability of
extracted ADI-R variables in the DAs is reflected in classification
matrices that show the number and percentage of correctly and
incorrectly identified subjects.
22q11DS-ASD versus heterogeneous ASD. Discriminant
analysis (DA) involving ADI-R domain subscale (called ‘‘labels’’ in
the ADI-R, see Table S1) scores extracted labels S3, C1, R3, and
R4 which resulted in a correct classification of 80% of the
22q11DS subjects and 78% of the heterogeneous ASD subjects.
Box’s M test for equal population covariance matrices was not
significant (P=0.35). Wilks’ lambda =0.83, x
2 (5) =74.5,
P,.0001. In the DA of the autism diagnostic interview-revised
(ADI-R) algorithm items, 12 items were extracted. This resulted in
a correct classification of 95% of the 22q11DS subjects and 93% of
the heterogeneous ASD subjects (Table 2). Box’s M test for equal
population covariance matrices was not significant (P=0.08).
Wilks’ lambda =0.58, x
2 (12)=217.7, P,.0001. Table 3 and
Table 1. Sample characteristics.
Gender
Sample N F M Age ± SD TIQ ± SD
22q11DS-ASD 39 18 21 13.262.6 66.1613.3
KS-ASD 14 0 14 13.763.0 81.5613.0
Heterogeneous ASD 372 56 316 10.663.7 98.7618.7
KS-ASD = Klinefelter syndrome with Autism Spectrum Disorder, 22q11DS-ASD
= 22q11 deletion syndrome with Autism Spectrum Disorder. F= Female,
M=Male, TIQ= average total IQ score.
doi:10.1371/journal.pone.0010887.t001
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respectively with the discriminant coefficients for the DA of
22q11DS+ASD versus heterogeneous ASD.
KS-ASD versus heterogeneous ASD. In the DA of KS-ASD
versus heterogeneous ASD involving ADI-R labels, only label A2
was extracted which resulted in a correct classification of 86% of
the KS subjects and 65% of the heterogeneous ASD subjects.
Box’s M test for equal population covariance matrices was not
significant (P=0.91). Wilks’ lambda =0.97, x
2 (1) =10.4,
P=.001. In the DA involving the autism ADI-R items, only 3
out of 37 items were extracted. This resulted in a correct
classification of 71% of the KS subjects and 80% of the
heterogeneous subjects with ASD (Table 2). Box’s M test was
not significant (P=0.63). Wilks’ lambda =0.91, x
2 (3)=34.50,
P,.001. Table 3 and Table 4 state the description of the extracted
labels and items respectively with the discriminant coefficients for
the DA of KS-ASD versus heterogeneous ASD.
A three-group DA (ie 22q11-ASD vs. KS-ASD vs. heteroge-
neous ASD) involving ADI-R items resulted in a correct
classification of 92.3% of the 22q11DS-ASD subjects, 78.6% of
the KS-ASD subjects, and 76.4% of the heterogeneous ASD
subjects (see Table S3) on the basis of 12 extracted items. Box’s M
test was not significant (P=0.25). Wilks’ lambda for function
1=0.55, x
2 (24)=250.86, P,.0001, and for function 2 Wilks’
lambda =0.90, x
2 (11)=42.04, P,.0001. The 3-group percent-
ages were similar to the results of the individual 22q11DS-ASD
and KS-ASD to heterogeneous ASD ADI-R item comparisons.
Figure 2 is the plot of the individual discriminant coefficients of the
3-group discriminant analysis. It illustrates that 22q11DS-ASD is
predominantly discriminated from heterogeneous ASD by func-
tion 2, KS-ASD from heterogeneous ASD by function 1. Table S4
states the description of the extracted items with the discriminant
coefficients for the 3-group DA. No additional items were
extracted for the three-group comparison than had been extracted
in both separate 22q11DS-ASD and KS-ASD versus heteroge-
neous ASD comparisons. In addition, 4 items that were extracted
in the 2-group comparisons were not extracted for the 3-group
comparisons (items 38, 49 and 51 out of the 22q11DS-ASD versus
Heterogeneous ASD sample and item 62 out of the KS-ASD
versus heterogeneous ASD comparisons).
Table S5 provides an overview of all the extracted ADI-R in the
different DAs. Table S6 contains a verifying calculation regarding
the stability of the DA results.
Discussion
Our results indicate that the clinical heterogeneity of ASDs might
be reduced when subgroups based on a specific genotype are
extracted from the overall genetically heterogeneous ASD popula-
tion. A substantially lower autistic symptom variance was shown in
Figure 1. Mean number of ADI-R items reaching autistic criterion (ADI-R score = 2). * P,0.002, ** P,0.0001, univariate analysis of
variance.
doi:10.1371/journal.pone.0010887.g001
Table 2. Classification matrix of the discriminant analyses of 22q11DS-ASD and KS-ASD versus heterogeneous ASD through ADI-R













n=39 4 80% (31) 12 95% (37)




n=14 1 86% (12) 3 71% (10)
n=372 65% (242) 80% (298)
doi:10.1371/journal.pone.0010887.t002
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heterogeneous ASD sample. Further analysis revealed that the
symptom profiles of the two studied genetic ASD disorders could be
robustly discriminated from the heterogeneous ASD profiles
through a limited number of autistic subscales and symptoms. In
our opinion, these results support the notion of the existence of
genetic subphenotypes within the ASD population. The lack of
overlap in the discriminating ADI-R labels and items between KS-
ASD and 22q11DS-ASD could indicate that both syndromes
represent ASD profiles that cluster around different specific points
in the total ASD diagnostic space, which was also suggested by the
results of the three-group analysis. It should be emphasized that
genetic disorder ASD subphenotypes are expected to overlap with
profiles present among heterogeneous samples, as all are diagnosed
according to the same DSM-IV-TR/ADI-R criteria. The premise
of an overlap of ASD subphenotypes between carriers and non-
carriers of large impact variants raises interesting questions. It could
be speculated that autistic symptom profiles out of the heteroge-
neousASDpopulationthatoverlapwithsymptomprofilesrelatedto
specific genotypes can possibly point to convergent etiologies.
Several limitations should be addressed. The data were
gathered from different studies, however, all studies were
performed by the authors of this paper, and the diagnostic
instruments were identical between the studies. The 22q11DS-
ASD and KS-ASD subjects were not selected form an original
ASD sample, but derived from psychiatric surveys among children
with 22q11DS and KS samples. It would have been preferable if
all subjects had been recruited in the same way. However, this
would require unfeasibly large ASD samples to extract a sufficient
number of 22q11-DS and KS-ASD cases. Although the ASD
subjects with 22q11DS and KS and the heterogeneous ASD
subjects fulfilled the same DSM-IV-TR clinical and ADI-R
criteria, the average clinical threshold for suspecting ASD could
have been different in the heterogeneous sample. Therefore,
ascertainment bias cannot be ruled out. However, we did not aim
to validate the association of 22q11DS and KS with ASD but
rather investigated whether specific genotypes can confer specific
autistic symptom profiles.
We do realize that reliability for the ADI-R is typically at the level
of overall diagnosis, or subdomain area and that the ADI-R was not
originallydesigned asa dimensionalmeasure.Nonetheless wefound
the largest contrast between the different groups at the level of
individual symptom items, while the DA involving ADI-R label
subscales also delivered better results than expected by chance.
Table 3. Description of extracted ADI-R labels with discriminant function coefficients for the discriminant analyses of 22q11DS-
ASD and KS-ASD versus heterogeneous ASD.
Sample Label no Label description Function
22q11DS-ASD S3 Lack of shared enjoyment .417
C1 Lack of, or delay in, spoken language and failure to compensate through gesture .669
R3 Stereotyped and repetitive motor mannerisms .274
R4 Preoccupations with part of objects or non-functional elements of material .315
KS-ASD S2 Relative failure to initiate or sustain conversational interchange 1.000
Domain S = Qualitative Abnormalities in Reciprocal Social Interaction, Domain C = Qualitative Abnormalities in Communication, Domain R = Restricted, Repetitive,
and Stereotyped Patterns of Behavior.
doi:10.1371/journal.pone.0010887.t003
Table 4. Description of extracted ADI-R items with discriminant function coefficients for the discriminant analyses of 22q11DS-
ASD and KS-ASD versus heterogeneous ASD.
Sample Item no Item description Domain Function
22q11DS-ASD 38 Neologisms/Idiosyncratic Language C 0,215
43 Nodding C 0,270
45 Conventional/Instrumental Gestures C 0,229
49 Imaginative Play With Peers S 0,192
50 Direct Gaze S 0,230
51 Social Smiling S 0,214
52 Showing and Directing Attention S 0,313
57 Range of Facial Expressions Used to Communicate S 20,609
58 Inappropriate Facial Expressions S 0,221
67 Unusual Preoccupations R 20,648
68 Circumscribed Interests R 0,352
KS-ASD 34 Social Verbalization/Chat C .215
53 Offering to Share S .270
62 Interest in Children S .229
Domain S = Qualitative Abnormalities in Reciprocal Social Interaction, Domain C = Qualitative Abnormalities in Communication, Domain R = Restricted, Repetitive,
and Stereotyped Patterns of Behavior.
doi:10.1371/journal.pone.0010887.t004
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nature of the discrimination symptoms. Similar assessments in
other larger ASD cohorts are required to prove whether the
current approach is feasible for ‘‘reversed phenotype’’ efforts.
Additional measures such as the Social Responsiveness Scale or
the Autism Diagnostic Observation Schedule (ADOS) can possibly
aid to enhance specificity of phenotype descriptions [21,22].
The current findings could suggest that the KS and 22q11DS
genotypes do not seem to merely augment heterogenic and
complex genetic susceptibility, i.e. lower the ASD threshold in an
aspecific way. Rather, our results could suggest that the strong
influence of a specific genetic variant leads to an ASD
subphenotype that is relatively specific with an increased within-
group symptom homogeneity in comparison to the heterogeneous
ASD population. Based upon these observations we hypothesize
that the increased symptom homogeneity is mainly driven by the
effect of one (or limited) genetic pathway(s). In contrast, the
phenotype observed in the general ASD population is most likely
mediated by the interplay of various combinations of all culprit
causative genetic pathways, and therefore associated with larger
ASD symptom heterogeneity. This consideration was emphasized
in recent overview of advancements in genetic studies of complex
traits: ‘‘For a substantial number of common diseases the newly
identified pathways suggest that molecular subphenotypes may
exist; that is, although a number of different pathways might
potentially be involved in the development of a particular disease
when all cases are considered, in any individual with the disease
only one or a subset of these pathways might be involved’’ [23].
Other ASD subphenotypes related to newly identified genetic
variants (e.g. 1q21 duplication or deletion, the 22q13.3 deletion
and the duplication of the 15q11–13 region) may be identified
when properly studied. This could ultimately lead to a dissection of
the ASD phenotype into a proportion of ‘‘genetic subtypes’’, and a
remaining group of ASD patients in whom the ASD phenotype is
the resultant of a more complex interaction between common
genetic variants and environmental factors.
In conclusion, the current findings support the possibility that
reduced genetic heterogeneity can be associated with reduced
ASD symptom heterogeneity. The method of the current study
using symptom variance and discrimination analysis involving the
widely used ADI-R offers a relatively straightforward possibility for
assessing genotype-ASD relationships. The assessments aim to
initiate further reverse phenotype strategies, especially given the
accumulating evidence for the existence of genetic variants of large
effect in a substantial proportion of the ASD population.
Methods
Participants
The Dutch Central Committee on Research Involving Human
Subjects had approved the research protocol. Patient associations
and centers for clinical genetics, and pediatrics were involved in
Figure 2. Plot of individual subject canonical function coefficients of the 3-group discriminant analysis for heterogeneous ASD
(grey dots) versus 22q11DS-ASD (red dots) versus KS-ASD (blue dots), the larger dots represent the group centroids. 22q11DS-ASD is
predominantly discriminated from heterogeneous ASD by function 1, KS-ASD from heterogeneous ASD by function 2.
doi:10.1371/journal.pone.0010887.g002
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which the subjects for the present study were selected (see below).
A newsletter presented on the web or in writing, had informed
parents and children of the aim and methods of the study. Parents
and children of had to apply actively for participation in the study
by contacting the research team. Subsequently they were sent
written information about the selection criteria and the implica-
tions of participation in the study. They were invited for
assessment if they met the inclusion criteria. Written informed
consent was obtained from participants (if older than 12 years of
age) and their parents or guardians according to the declaration of
Helsinki.
22q11DS or KS subjects were selected for this study if they had
been diagnosed with an ASD via previous surveys on general
psychopathology on children with 22q11DS (n=90) and Kline-
felter Syndrome (KS) sample (n=51), all 47, XXY none higher
aneuploidies, no mosaics). (See [16,17] for more extensive details
on recruitment and further characteristics of the patient samples).
This survey had resulted in an ASD classification in 14 of the 51
KS boys (14/51=27%) and 39 of the 90 22q11DS children (39/
90=43%). The classification of an autism spectrum disorder
(ASD) was made on the basis of DSM-IV-TR standardized
interviews and the Autism Diagnostic Interview (ADI-R) [24].
Videotapes of all subjects and the DSM-IV-TR/ADI-R outcomes
were discussed in a consensus meeting headed by the head of the
department. The consensus meeting served to control for
procedural mistakes and to verify whether the classifications
through the DSM-IV-TR and ADI-R interviews were in
agreement with the clinical judgment. All 22q11DS and KS
subjects with an ASD met ADI-R thresholds and DSM-IV-TR
criteria.
A genetically heterogeneous ASD sample was recruited as part
of a genetic study of autism and from a clinical sample of patients
referred to the department of child and adolescent psychiatry for
diagnostic reasons. Thus, these subjects were unascertained for
their genotype and should therefore represent a reference sample
of maximal genetic heterogeneity. Inclusion criteria were: age four
years or older, no severe medical or neurological illness, IQ.40.
The final sample consisted of 372 verbal subjects. Study
participants ranged in age from 4 to 20 years. Similar to the
ASD cases obtained from the 22q11 and XXYDS cohorts, all
subjects out of the heterogeneous ASD sample had been evaluated
in consensus meetings to confirm ASD diagnosis through the
interviews and all subjects met ADI-R thresholds.
IQ had been assessed by means of the Dutch versions of the
Wechsler scales (WPSSI WISC III and WAIS) [25–27] in the KS
and 22q11DS sample and in a significant part of the ASD
heterogeneous group (65%). IQ scores of the heterogeneous ASD
sample that could not be assessed with the Wechsler scales have
been assessed with the RAVEN Progressive Matrices [28] the
Mullen Scales of Early Learning [29] or the Snijders-Oomen non-
verbal intelligence test-Revised [30]. No difference in intelligence
level between those with and those without ASDs had been found
in both the 22q11DS and KS samples in the original psychiatric
surveys (see [16,17]).
Measurements
ADI-R subscale and symptom variables were entered in the
statistical analyses for phenotype comparisons. The ADI–R is an
established ‘gold standard’ in diagnostic/phenotypic evaluations of
autism. It is an extensive clinical interview administered to the
parents. The interview focuses on the three core or so called
‘‘content’’ domains of autism (i.e. qualitative abnormalities in
social interaction (S), qualitative abnormalities in communication
(C) and stereotyped and repetitive behaviors (R) [24]. ADI-R items
are coded for these domains and also for an ‘‘age of onset’’
domain. A classification of an autism spectrum disorder is applied
when scores in all domains are met or when scores are met in two
core domains and meet criteria on the ‘‘age of onset’’ domain, but
are one point away from meeting autism criteria in the remaining
core domain. Reliability of the ADI-R in a population with mild to
moderate mental retardation has been established [31].
The ADI-R may also be used to assess profiles of autistic
symptomatology [32,33]. The ADI–R algorithm is composed of
37 symptom ‘‘items’’. These items were originally selected as a
minimum for optimal ASD classification [24]. ADI-R labels
consist of 2 to 5 items and are directly related to the DSM-IV-TR
criteria of an Autistic Disorder. As a result, 12 ADI-R labels are
used. Each ADI-R domain consists of 4 labels, eg S1-4, C1-4 and
R1-4. Items are coded as 0 (ASD behavioural symptom specified
not present), 1 (specified behaviour not sufficient to code ‘‘2’’) or 2
(specified ASD symptom present). Maximum label scores thus
range from 4–10. An overview of the description of the ADI-R
items, labels and the ADI-R domains of the algorithm is provided
in Tables S1 and S2.
Statistical analyses
Symptom homogeneity was operationalized as the (inverse of
the) mean number of ADI-R algorithm items within each ASD
group on which the subjects scored clearly in the autistic range, i.e.
ADI-R item score =2. Thus, per subject, the number of items
with score =2 were counted. A lower number of ADI-R items that
reached the autism criterion can be considered indicative of a
relative reduction in symptom heterogeneity. Differences between
groups in number of ADI-R items on which the autism criterion
was reached were analyzed by means of a univariate analysis of
variance, with post hoc Bonferroni multiple comparisons.
Discriminant analyses (DA) were performed to determine
whether the genetic disorder ASD subsamples could be differen-
tiated from the heterogeneous ASD sample on the basis of ADI-R
variables. The analyses addressed the question to what extent
ADI-R label and/or ADI-R symptom item profiles could
successfully discriminate 22q11DS or KS ASD profiles from the
heterogeneous ASD sample profile (i.e., 22q11DS+ASD vs.
heterogeneous ASD, and KS+ASD vs. heterogeneous ASD). In
addition, three group DAs were performed to explore the
separation of the three groups by means of 2 discriminant
functions.
For all discriminant analyses, stepwise Wilks’ lambda was used,
with probability of F for entry and removal of variables set at 0.5
and 0.10 respectively. For classification the within-group covari-
ance matrices were used and prior probability was set to equal for
all groups.
Supporting Information
Table S1 ADI-R algorithm items sorted by labels and domains.
Found at: doi:10.1371/journal.pone.0010887.s001 (0.07 MB
DOC)
Table S2 ADI-R algorithm items sorted by number.
Found at: doi:10.1371/journal.pone.0010887.s002 (0.05 MB
DOC)
Table S3 Classification matrix of the 3-group discriminant
analysis of heterogeneous ASD versus KS-ASD versus 22q11DS-
ASD.
Found at: doi:10.1371/journal.pone.0010887.s003 (0.04 MB
DOCX)
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ADI-R items extracted in the 3-group discriminant analysis of
heterogeneous ASD versus KS-ASD versus 22q11DS-ASD.
Found at: doi:10.1371/journal.pone.0010887.s004 (0.04 MB
DOC)
Table S5 Overview of extracted ADI-R items with subsequent
labels in the different discriminant analyses. DA1 =22q11DS-
ASD versus heterogeneous ASD. DA2 = KS-ASD versus
heterogeneous ASD. D3 =3-group group comparison of
22q11DS-ASD versus KS-ASD versus heterogeneous ASD.
Found at: doi:10.1371/journal.pone.0010887.s005 (0.05 MB
DOC)
Table S6 Results for stability calculations of DAs. ADI-R items
extracted in the 4 additional DAs, sorted by correspondence/item
number. To verify whether the stepwise analysis of the three
groups DA did provide stable solution, the stepwise DA to separate
the three groups has been repeated another four times, with half of
the sample of subjects with heterogeneous ASD. Thereto the
sample was divided in four quarters, called Q1 to Q4. The DA has
been performed with inclusion of the heterogeneous subsamples
Q1+Q2, Q3+Q4, Q1+Q3, and Q2+Q4. The ‘solutions’ are
compared with each other and with the result of the DA presented
in the paper that included the total sample of subjects with
heterogeneous ASD. The comparison is focused on the number
and type of items that are extracted. Table S6 shows that the
solutions are highly similar. The number of items extracted varies
between 10 and 15. There are 8 items that appear in each DA,
there is 1 items that appears in 3 DAs, there are 7 items that
appear in 2 DAs, there is 1 item appearing in only one DA.
Comparing the four solutions with the results of the original DA
presented in the paper shows that all of the 12 items extracted in
this DA, all show up in one or more one of the other DAs. Eight
items of the original DA show up in all other analyses, the other
four items of the original DA appear in at least two of the other
DAs.
Found at: doi:10.1371/journal.pone.0010887.s006 (0.06 MB
DOC)
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